Alternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cells

IntroductionInsulin analogues are designed to have improved pharmacokinetic parameters compared to regular human insulin. This provides a sustained control of blood glucose levels in diabetic patients. All novel insulin analogues are tested for their mitogenic side effects, however these assays do not take into account the molecular mode of action of different insulin analogues. Insulin analogues can bind the insulin receptor and the insulin-like growth factor 1 receptor with different affinities and consequently will activate different downstream signaling pathways.MethodsHere we used a panel of MCF7 human breast cancer cell lines that selectively express either one of the isoforms of the INSR or the IGF1R. We applied a transcriptomics approach to assess the differential transcriptional programs activated in these cells by either insulin, IGF1 or X10 treatment.ResultsBased on the differentially expressed genes between insulin versus IGF1 and X10 treatment, we retrieved a mitogenic classifier gene set. Validation by RT-qPCR confirmed the robustness of this gene set. The translational potential of these mitogenic classifier genes was examined in primary human mammary cells and in mammary gland tissue of mice in an in vivo model. The predictive power of the classifier genes was evaluated by testing all commercial insulin analogues in the in vitro model and defined X10 and glargine as the most potent mitogenic insulin analogues.ConclusionsWe propose that these mitogenic classifier genes can be used to test the mitogenic potential of novel insulin analogues as well as other alternative molecules with an anticipated affinity for the IGF1R.

[1]  J. Valcárcel,et al.  RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. , 2013, Molecular cell.

[2]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[3]  A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. , 2002, The Journal of clinical endocrinology and metabolism.

[4]  J. Coebergh,et al.  Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study , 2011, Diabetologia.

[5]  Haibo Zhou,et al.  Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin , 2013, Diabetes Care.

[6]  M. Pollak.  The insulin and insulin-like growth factor receptor family in neoplasia: an update , 2012, Nature Reviews Cancer.

[7]  L. Hemkens,et al.  Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study , 2009, Diabetologia.

[8]  A. Ferrara,et al.  Cohort Study of Insulin Glargine and Risk of Breast, Prostate, and Colorectal Cancer Among Patients With Diabetes , 2013, Diabetes Care.

[9]  T. Katagiri,et al.  Early Growth Response 4 Is Involved in Cell Proliferation of Small Cell Lung Cancer through Transcriptional Activation of Its Downstream Genes , 2014, PloS one.

[10]  N. Tennagels,et al.  In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites , 2010, PloS one.

[11]  T. Heise,et al.  Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes , 2012, Diabetes Care.

[12]  L. Qin,et al.  Epidermal Growth Factor Receptor (EGFR) Signaling Promotes Proliferation and Survival in Osteoprogenitors by Increasing Early Growth Response 2 (EGR2) Expression* , 2013, The Journal of Biological Chemistry.

[13]  A. Toker,et al.  Signalling specificity in the Akt pathway in breast cancer. , 2014, Biochemical Society transactions.

[14]  B. Water,et al.  Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel , 2014, Archives of Toxicology.

[15]  D. Leroith,et al.  Investigating new therapeutic strategies targeting hyperinsulinemia's mitogenic effects in a female mouse breast cancer model. , 2013, Endocrinology.

[16]  Pierre R. Bushel,et al.  Assessing Gene Significance from cDNA Microarray Expression Data via Mixed Models , 2001, J. Comput. Biol..

[17]  P. Home,et al.  Combined randomised controlled trial experience of malignancies in studies using insulin glargine , 2009, Diabetologia.

[18]  Takashi Suzuki,et al.  Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-meditated invasion and a potent prognostic factor. , 2007, Endocrine-related cancer.

[19]  In vivo murine hepatic microRNA and mRNA expression signatures predicting the (non-)genotoxic carcinogenic potential of chemicals , 2014, Archives of Toxicology.

[20]  S. Yusuf,et al.  The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia , 2014, Diabetes Care.

[21]  G. Pandini,et al.  Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling , 2010, Diabetologia.

[22]  N. Tennagels,et al.  The metabolic and mitogenic properties of basal insulin analogues , 2013, Archives of physiology and biochemistry.

[23]  R. Jorissen,et al.  PHLDA1 expression marks the putative epithelial stem cells and contributes to intestinal tumorigenesis. , 2011, Cancer research.

[24]  H. Klein,et al.  Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. , 1996, The Biochemical journal.

[25]  B. Hansen.  Insulin Analogues with Increased Mitogenic Potency – Are they Safe? , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[26]  G. Steineck,et al.  Insulin glargine use and short-term incidence of malignancies — a three-year population-based observation , 2011, Acta oncologica.

[27]  U. Kees,et al.  Deregulated expression of connective tissue growth factor (CTGF/CCN2) is linked to poor outcome in human cancer , 2015, International journal of cancer.

[28]  R. Tollenaar,et al.  Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10 , 2011, Breast Cancer Research.

[29]  Gordon K. Smyth,et al.  Use of within-array replicate spots for assessing differential expression in microarray experiments , 2005, Bioinform..

[30]  A. Zell,et al.  Cross-Platform Toxicogenomics for the Prediction of Non-Genotoxic Hepatocarcinogenesis in Rat , 2014, PloS one.

[31]  H. Nagase,et al.  NR4A3, a possibile oncogenic factor for neuroblastoma associated with CpGi methylation within the third exon , 2014, International journal of oncology.

[32]  B. van de Water,et al.  Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/+WAPCre mouse model , 2015, Breast Cancer Research.

[33]  E. Gale,et al.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes , 2009, Diabetologia.

[34]  L. Schäffer,et al.  Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. , 2000, Diabetes.

[35]  F. Hu,et al.  The global implications of diabetes and cancer , 2014, The Lancet.

[36]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[37]  C Decaestecker,et al.  Epithelial expression of FHL2 is negatively associated with metastasis-free and overall survival in colorectal cancer , 2013, British Journal of Cancer.

[38]  Y. Joo,et al.  Expression of early growth response-1 in colorectal cancer and its relation to tumor cell proliferation and apoptosis. , 2014, Oncology reports.

[39]  David W. Wyatt,et al.  Mechanism of Suppression of Chromosomal Instability by DNA Polymerase POLQ , 2014, PLoS genetics.

[40]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[41]  the Scottish Diabetes Research Network Epidemiology Group.  Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group , 2009, Diabetologia.